GlassScriptPhysician profile
Marilyn Mora
NPI 1821544032
$12,315.06
in general payments reported to CMS, 2019-2025
34 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,566 · 2022: $2,108 · 2023: $2,672 · 2024: $2,973 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,545 · Education: $96.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,544.54 |
| Education | $96.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,844.80 | 2021-2025 | |
| Amgen INC. | $2,841.01 | 2021-2025 | Enbrel, Evenity, Otezla |
| Ucb, INC. | $1,494.70 | 2021-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $801.26 | 2021-2025 | |
| Lilly USA, LLC | $609.75 | 2021-2024 | Taltz |
| Glaxosmithkline, LLC. | $429.21 | 2021-2025 | Benlysta |
| Janssen Biotech, INC. | $429.06 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Organon LLC | $361.90 | 2023-2025 | Hadlima, Renflexis |
| Radius Health, INC. | $336.28 | 2021-2025 | Tymlos |
| Genzyme Corporation | $278.06 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $240.90 | 2023-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.34 | 2021-2025 | Ofev, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $210.75 | 2021-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $143.10 | 2022-2025 | Orencia |
| Ferring Pharmaceuticals INC. | $117.83 | 2021-2024 | Euflexxa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $115.35 | 2021-2023 | Krystexxa |
| Sobi, INC | $94.80 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $90.05 | 2021-2024 | Strensiq |
| Fresenius Kabi USA, LLC | $74.09 | 2023-2025 | |
| Genentech USA, INC. | $65.49 | 2023-2024 | Actemra, Rituxan |
| Aurinia Pharma U.S., INC. | $57.54 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $55.58 | 2022-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $55.55 | 2021-2024 | |
| Kyowa Kirin, INC. | $53.83 | 2023-2025 | Crysvita |
| Teva Pharmaceuticals USA, INC. | $50.95 | 2023-2024 | Truxima |
| Actelion Pharmaceuticals US, INC. | $50.70 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $39.82 | 2024 | Arcalyst |
| Biogen, INC. | $29.32 | 2024 | |
| Celltrion USA INC. | $25.83 | 2023 | Yuflyma |
| Octapharma USA, INC. | $22.95 | 2024 | Octagam Immune Globulin (Human) |
| Bioventus LLC | $18.79 | 2021 | |
| Mylan Institutional INC. | $17.46 | 2023 | Hulio |
| Kiniksa Pharmaceuticals, LTD. | $15.93 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $6.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.